Therapeutic Targeting of mTORC2 in mTORopathies.

Dentel, Brianne; Escamilla, Christine Ochoa; Tsai, Peter T

Dentel, Brianne; Escamilla, Christine Ochoa; Tsai, Peter T.

Afiliación

Dentel B; Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Escamilla CO; Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Tsai PT; Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: peter.tsai@utsouthwestern.edu.

Neuron ; 104(6): 1032-1033, 2019 12 18.

Article en En | MEDLINE | ID: mdl-31951535

RESUMEN

Dysregulated mTOR contributes to neurodevelopmental dysfunction. A new study (Chen et al., 2019) demonstrates that suppression of mTORC2, not mTORC1, ameliorates survival, seizures, and abnormal behaviors in a Pten mutant model, highlighting mTORC2 as a potential therapeutic target in mTORopathies.

Asunto(s)

Sirolimus; Diana Mecanicista del Complejo 1 de la Rapamicina; Diana Mecanicista del Complejo 2 de la Rapamicina

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sirolimus Idioma: En Revista: Neuron Asunto de la revista: NEUROLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google